Press Release: BD Onclarity™ HPV Assay Receives FDA Approval for Use with Both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test

BD Onclarity HPV Assay

The BD Onclarity™ HPV Assay has received FDA Approval for use with both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test, which expands access to the HPV test that more precisely identifies patients’ risk for cervical cancer.

“When more people with a cervix are better able to manage their health through more accurate and precise testing, we are taking another step forward toward eliminating cervical cancer in our lifetimes,” said Dr. Jeff Andrews, Vice President of Medical Affairs for BD.

ThinPrep is a trademark of Hologic, Inc.

Latest resources

Discover our latest articles, webinars, press releases and updates in women's health.

Contemporary OB/GYN
Cervical Cancer | News & Updates
Contemporary OB/GYN: Harris Poll study from BD reveals knowledge gap and inequity in HPV screening and cervical cancer
Business Insider
Cervical Cancer | News & Updates
Business Insider: Getting the HPV vaccine and regular testing can help protect you from high-risk HPV strains that cause cancer
James Walker
MLO Online: COVID-19’s impact on testing practices for STIs